UY25519A1 - PROCEDURE FOR PREPARING VITRONECTIN RECEPTOR ANTAGONIST - Google Patents
PROCEDURE FOR PREPARING VITRONECTIN RECEPTOR ANTAGONISTInfo
- Publication number
- UY25519A1 UY25519A1 UY25519A UY25519A UY25519A1 UY 25519 A1 UY25519 A1 UY 25519A1 UY 25519 A UY25519 A UY 25519A UY 25519 A UY25519 A UY 25519A UY 25519 A1 UY25519 A1 UY 25519A1
- Authority
- UY
- Uruguay
- Prior art keywords
- phenyl
- preparing
- formula
- vitronectin receptor
- compounds
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Procedimiento para preparar compuestos farmacéuticamente activos de fórmula general (Ia) representada en la figura 1, o una sal farmacéuticamente aceptable del mismo, donde: X e Y son independientemente CR`R`, NR`o S; R1 es alquil C0-C6-het, alquil-C0-C6-Ar, -H, -CN, o -S(O)kR9; R2 es un grupo de los representados en la figura 2, donde W es -(CHR9)a-U-(CHR9)b-; el procedimiento comprende hacer reaccionar un compuesto de fórmula (IV) con un compuesto de fórmula (V), ambas representadas en la figura 3, con todos los grupos funionales protegidos, siendo L1 OH u halo, y luego sepearar todos los grupos protectores, y opcionalmente formar una sal farmacéuticamente aceptable. Ejemplos de compuestos de fórmula general: Ácido (+)-3-fenil-4-[3-(piridin-2-il)amino-1-prpiloxifenil]butanoico; Ácido de (+)-3-fenil-4-[4-[2-[6-(metilamino)-piridin-2-il]-1-etoxi]fenil]butanoico; entre otros. Estos compuestos inhiben el receptor de vitronectina y son útiles para el tratamiento de inflamación, cáncer y transtornos cardiovasculares, tales como arteriosclerosis y restenosis, y enfermedades en las que la resorción ósea es un factor, tal como la osteoporosis.Process for preparing pharmaceutically active compounds of general formula (Ia) represented in figure 1, or a pharmaceutically acceptable salt thereof, where: X and Y are independently CR`R`, NR` or S; R1 is C0-C6 alkyl-het, -C0-C6 alkyl-Ar, -H, -CN, or -S (O) kR9; R2 is a group of those depicted in Figure 2, where W is - (CHR9) a-U- (CHR9) b-; The process comprises reacting a compound of formula (IV) with a compound of formula (V), both represented in figure 3, with all functional groups protected, being L1 OH or halo, and then separating all protecting groups, and optionally form a pharmaceutically acceptable salt. Examples of compounds of the general formula: (+) - 3-phenyl-4- [3- (pyridin-2-yl) amino-1-prpyloxyphenyl] butanoic acid; (+) - 3-Phenyl-4- [4- [2- [6- (methylamino) -pyridin-2-yl] -1-ethoxy] phenyl] butanoic acid; among others. These compounds inhibit the vitronectin receptor and are useful for the treatment of inflammation, cancer and cardiovascular disorders, such as arteriosclerosis and restenosis, and diseases in which bone resorption is a factor, such as osteoporosis.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7761098P | 1998-03-10 | 1998-03-10 | |
| US9606398P | 1998-08-11 | 1998-08-11 | |
| UY25421A UY25421A1 (en) | 1998-03-10 | 1999-03-10 | VITRONECTIN RECEPTOR ANTAGONISTS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY25519A1 true UY25519A1 (en) | 1999-12-13 |
Family
ID=26759473
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY25421A UY25421A1 (en) | 1998-03-10 | 1999-03-10 | VITRONECTIN RECEPTOR ANTAGONISTS |
| UY25519A UY25519A1 (en) | 1998-03-10 | 1999-05-19 | PROCEDURE FOR PREPARING VITRONECTIN RECEPTOR ANTAGONIST |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY25421A UY25421A1 (en) | 1998-03-10 | 1999-03-10 | VITRONECTIN RECEPTOR ANTAGONISTS |
Country Status (24)
| Country | Link |
|---|---|
| EP (1) | EP1061921A4 (en) |
| JP (1) | JP2002506033A (en) |
| KR (1) | KR20010041812A (en) |
| CN (1) | CN1299282A (en) |
| AP (1) | AP2000001898A0 (en) |
| AR (1) | AR015241A1 (en) |
| AU (1) | AU758498B2 (en) |
| BG (1) | BG104824A (en) |
| BR (1) | BR9908636A (en) |
| CA (1) | CA2323208A1 (en) |
| CO (1) | CO5080762A1 (en) |
| DZ (1) | DZ2741A1 (en) |
| EA (1) | EA200000921A1 (en) |
| HU (1) | HUP0101143A3 (en) |
| ID (1) | ID26223A (en) |
| IL (1) | IL138245A0 (en) |
| NO (1) | NO20004503L (en) |
| OA (1) | OA12189A (en) |
| PE (1) | PE20000323A1 (en) |
| PL (1) | PL342881A1 (en) |
| SK (1) | SK13292000A3 (en) |
| TR (1) | TR200002625T2 (en) |
| UY (2) | UY25421A1 (en) |
| WO (1) | WO1999045927A1 (en) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19939980A1 (en) * | 1999-08-24 | 2001-03-01 | Merck Patent Gmbh | Inhibitors of the integrin alphavbeta¶3¶ |
| DE19939981A1 (en) * | 1999-08-24 | 2001-03-01 | Merck Patent Gmbh | New inhibitors of the integrin alphavß3 |
| EG24179A (en) * | 1999-09-07 | 2008-09-28 | Smithkline Beecham Corp | Vitronectin receptor antagonists |
| US6881736B1 (en) | 1999-09-07 | 2005-04-19 | Smithkline Beecham Corporation | Vitronectin receptor antagonists |
| GB9930570D0 (en) * | 1999-12-23 | 2000-02-16 | Pfizer Ltd | Therapy |
| US6448278B2 (en) | 1999-12-23 | 2002-09-10 | Pfizer Inc. | Procollagen C-proteinase inhibitors |
| FR2808798A1 (en) * | 2000-05-09 | 2001-11-16 | Hoechst Marion Roussel Inc | New N-heterocyclyl-aminoacid derivatives and analogs, are vitronectin analogs useful e.g. for treating osteoporosis, tumor growth or metastasis, inflammation or cardiovascular disease |
| AU2001269821A1 (en) | 2000-06-15 | 2001-12-24 | Barbara Chen | Cycloalkyl alkanoic acids as integrin receptor antagonists |
| US6531494B1 (en) | 2001-08-29 | 2003-03-11 | Pharmacia Corporation | Gem-substituted αvβ3 antagonists |
| US6645993B2 (en) | 2001-03-30 | 2003-11-11 | Warner-Lambert Company | 3-heterocyclylpropanohydroxamic acid PCP inhibitors |
| US6716842B2 (en) | 2002-04-05 | 2004-04-06 | Warner-Lambert Company, Llc | Antidiabetic agents |
| WO2005049589A2 (en) * | 2003-10-14 | 2005-06-02 | Cadila Healthcare Limited | Heterocyclic compounds for the treatment of hyperlipidemia, diabetes, obesity and similar diseases |
| RU2367661C2 (en) * | 2004-03-05 | 2009-09-20 | Тайсо Фармасьютикал Ко., Лтд. | Thiazole derivatives |
| UA87854C2 (en) | 2004-06-07 | 2009-08-25 | Мерк Энд Ко., Инк. | N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators |
| CN101228129A (en) | 2005-04-20 | 2008-07-23 | 詹森药业有限公司 | Fluorinated pyridine N-oxide thrombin modulators and process for N-oxidation of nitrogen containing heteroaryls |
| WO2015030189A1 (en) * | 2013-08-29 | 2015-03-05 | 京都薬品工業株式会社 | Novel aromatic compound and use thereof |
| HRP20211836T1 (en) | 2013-09-24 | 2022-03-04 | Fujifilm Corporation | Novel nitrogen-containing compound or salt thereof, or metal complex thereof |
| US10328082B2 (en) | 2014-05-30 | 2019-06-25 | Pfizer Inc. | Methods of use and combinations |
| WO2023275715A1 (en) | 2021-06-30 | 2023-01-05 | Pfizer Inc. | Metabolites of selective androgen receptor modulators |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR9612378A (en) * | 1995-12-29 | 1999-07-13 | Smithkline Beecham Corp | Vitronectin receptor antagonists |
| IL125030A0 (en) * | 1995-12-29 | 1999-01-26 | Smithkline Beecham Corp | Vitronectin receptor antagonists |
-
1999
- 1999-03-10 CN CN99805833A patent/CN1299282A/en active Pending
- 1999-03-10 AU AU29033/99A patent/AU758498B2/en not_active Ceased
- 1999-03-10 BR BR9908636-0A patent/BR9908636A/en not_active Application Discontinuation
- 1999-03-10 HU HU0101143A patent/HUP0101143A3/en unknown
- 1999-03-10 DZ DZ990042A patent/DZ2741A1/en active
- 1999-03-10 OA OA00000248A patent/OA12189A/en unknown
- 1999-03-10 TR TR2000/02625T patent/TR200002625T2/en unknown
- 1999-03-10 UY UY25421A patent/UY25421A1/en unknown
- 1999-03-10 KR KR1020007010091A patent/KR20010041812A/en not_active Application Discontinuation
- 1999-03-10 WO PCT/US1999/005232 patent/WO1999045927A1/en not_active Application Discontinuation
- 1999-03-10 ID IDW20001737A patent/ID26223A/en unknown
- 1999-03-10 AP APAP/P/2000/001898A patent/AP2000001898A0/en unknown
- 1999-03-10 CA CA002323208A patent/CA2323208A1/en not_active Abandoned
- 1999-03-10 JP JP2000535342A patent/JP2002506033A/en not_active Withdrawn
- 1999-03-10 AR ARP990101019A patent/AR015241A1/en not_active Application Discontinuation
- 1999-03-10 IL IL13824599A patent/IL138245A0/en unknown
- 1999-03-10 EA EA200000921A patent/EA200000921A1/en unknown
- 1999-03-10 SK SK1329-2000A patent/SK13292000A3/en unknown
- 1999-03-10 EP EP99909952A patent/EP1061921A4/en not_active Withdrawn
- 1999-03-10 PE PE1999000188A patent/PE20000323A1/en not_active Application Discontinuation
- 1999-03-10 PL PL99342881A patent/PL342881A1/en unknown
- 1999-03-10 CO CO99014712A patent/CO5080762A1/en unknown
- 1999-05-19 UY UY25519A patent/UY25519A1/en unknown
-
2000
- 2000-09-08 NO NO20004503A patent/NO20004503L/en unknown
- 2000-10-03 BG BG104824A patent/BG104824A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| UY25421A1 (en) | 2001-07-31 |
| AP2000001898A0 (en) | 2000-09-30 |
| CA2323208A1 (en) | 1999-09-16 |
| HUP0101143A3 (en) | 2002-12-28 |
| NO20004503L (en) | 2000-10-10 |
| JP2002506033A (en) | 2002-02-26 |
| PL342881A1 (en) | 2001-07-16 |
| EP1061921A1 (en) | 2000-12-27 |
| OA12189A (en) | 2006-05-09 |
| WO1999045927A1 (en) | 1999-09-16 |
| CN1299282A (en) | 2001-06-13 |
| PE20000323A1 (en) | 2000-05-24 |
| BR9908636A (en) | 2002-01-08 |
| AR015241A1 (en) | 2001-04-18 |
| BG104824A (en) | 2001-05-31 |
| SK13292000A3 (en) | 2001-06-11 |
| EP1061921A4 (en) | 2005-03-30 |
| CO5080762A1 (en) | 2001-09-25 |
| TR200002625T2 (en) | 2000-12-21 |
| EA200000921A1 (en) | 2001-04-23 |
| AU2903399A (en) | 1999-09-27 |
| IL138245A0 (en) | 2001-10-31 |
| KR20010041812A (en) | 2001-05-25 |
| ID26223A (en) | 2000-12-07 |
| AU758498B2 (en) | 2003-03-20 |
| HUP0101143A2 (en) | 2001-08-28 |
| DZ2741A1 (en) | 2003-09-08 |
| NO20004503D0 (en) | 2000-09-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY25519A1 (en) | PROCEDURE FOR PREPARING VITRONECTIN RECEPTOR ANTAGONIST | |
| UY24409A1 (en) | METALOPROTEASE MATRIX INHIBITORS | |
| NO20024217L (en) | 1,5-benzothiazepines and their use as hypolid agents | |
| CY1110382T1 (en) | PYRAZINE SUBSTITUTED ARYLENBENZODIAZEPINES | |
| SE0203754D0 (en) | New compounds | |
| NO20045103L (en) | Benzofused heteroarylamide derivatives of thienopyridines useful as therapeutic agents, pharmaceutical compositions comprising the same and methods for their use | |
| AR029634A1 (en) | USEFUL HETEROCICLIC DERIVATIVE COMPOUNDS AS ANTI-TARGET AGENTS, PHARMACEUTICAL COMPOSITION AND PROCESSING PROCEDURE | |
| KR950005817A (en) | A benzo-fused heterocyclic compound having a 5-membered ring, its preparation method, its use as a medicine, its use as a diagnostic agent and medicaments containing it | |
| AR017021A1 (en) | 2-HYDROXYACETIC ACID | |
| WO2002026712A3 (en) | Quaternary amines and related inhibitors of factor xa | |
| ES2158778B1 (en) | PAROXETINE SALT COMPOUNDS, THEIR PREPARATION AND USE, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. | |
| NO20051303L (en) | New benzoimidazole derivatives useful as antiproliferative agents | |
| DK1029853T3 (en) | Heteroaromatic bicyclic derivatives useful as anticancer agents | |
| DOP2001000170A (en) | USEFUL THIOPHEN DERIVATIVES AS ANTI-CHANCE AGENTS | |
| ES2070126T3 (en) | PIRIDAZINAMINE DERIVATIVES. | |
| NO992524L (en) | Concentrated bicyclic pyrimidine derivatives | |
| GB9213623D0 (en) | Therapeutic agents | |
| PE20020721A1 (en) | QUINUCLIDINE DERIVATIVES AS ANTIMUSCARINAL AGENTS M3 | |
| WO2001056989A3 (en) | Inhibitors of factor xa | |
| RU94044671A (en) | Use of nonpeptide antagonists of tachykinin receptors | |
| FI943142A (en) | Amide and urea derivatives which counteract high blood cholesterol levels, their preparation and therapeutic uses | |
| MX9307332A (en) | 3- (AMINOALKYLAMINE) -1,2-BENZSOXASOLES SUBSTITUTED AND RELATED COMPOUNDS. | |
| WO2005065074A2 (en) | Protection of tissues and cells from cytotoxic effects of ionizing radiation by abl inhibitors | |
| ES2100222T3 (en) | DERIVATIVES OF THE AMINOALCANSULFONICO ACID AND PHARMACEUTICAL COMPOUNDS TO USE TO PREVENT OR TREAT CARDIAC DISEASES. | |
| PA8426801A1 (en) | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF RHINITIS. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| DESI | Application deemed to be withdrawn |
Effective date: 20071105 |